This is your blog intro text.
BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it... Continue Reading
Government price fixing for U.S. medicines will cost lives, jobs, innovation Legislation that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter, according to a new analysis released by... Continue Reading
Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver,... Continue Reading
BIO President and CEO Michelle McMurry-Heath, M.D., Ph.D., sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on. India, South... Continue Reading
A new executive order from the Trump administration that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies, according to NCBIO, the... Continue Reading
